Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy

Shimada, Kyoko; Nagao, Shoji; Suzuki, Kazutoshi; Shibutani, Takashi; Yamamoto, Keizô; Jimi, Tomoatsu; Yano, Hiroko; Kitai, Miho; Shiozaki, Takaya; Yamaguchi, Satoshi

doi:10.1007/s10147-020-01706-w

Cited by 3 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Suppressive effect on HSR to carboplatin by PLD-C combination therapy was also confirmed by a Japanese randomized prospective study by Fujiwara et al, in which HSR was observed at 2.0% in PLD-C vs. 13.7% in gemcitabine plus carboplatin [20]. A retrospective study by Shimada et al, in which total of 414 patients (48: PLD-C group, 366: non-PLD-C group) were analyzed, found a 2.1% rate of HSR in a PLD-C group vs. 9.0% in a non-PLD-C group [21]. Based on these results, PLD-C may be a reasonable option for second-line chemotherapy continuing platinum combination chemotherapy while suppressing the frequency of HSR in the treatment of recurrent ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Hypersensitivity Reaction to Carboplatin in Gynecologic Cancer: A Case Report and a Review of the Literature

Aoyama

Ueda

Kuradome

et al. 2021

J UOEH

View full text Add to dashboard Cite

A combination chemotherapy of paclitaxel plus carboplatin (TC) is the most frequently used regimen for gynecological malignancies. As long as it is effective, a carboplatin-containing combination chemotherapy is used for every relapse. This implies that the number of platinum administrations and the frequency of hypersensitivity reaction (HSR) increase as the prognosis improves. When a patient develops HSR to carboplatin, we have three options: 1) desensitizing and continuing to use carboplatin, 2) switching to other platinum drugs, or 3) changing to a non-platinum drug. Here we report an experience of an HSR to carboplatin in a patient with recurrent uterine carcinosarcoma. The patient was treated by surgery and TC therapy initially, resulting in no residual disease. The patient relapsed 18 months after the completion of the first-line chemotherapy and was treated with TC therapy again as second-line. An HSR to carboplatin occurred at the 10th cycle of TC in total. We replaced the carboplatin with cisplatin. A chemotherapy including cisplatin and adriamycin was repeated without further HSR. We reviewed the literature regarding HSR to carboplatin and in this paper we summarize the management for dealing with it.

show abstract

Section: Discussionmentioning

confidence: 99%

Hypersensitivity Reaction to Carboplatin in Gynecologic Cancer: A Case Report and a Review of the Literature

Aoyama

Ueda

Kuradome

et al. 2021

J UOEH

View full text Add to dashboard Cite

show abstract

“…The first choice of PBC in our institution is PLD-C, owing to the high efficacy and low incidence of carboplatin hypersensitivity reactions in the CALYPSO trial and our study. 6,7 Other platinumbased combinations or carboplatin monotherapy were selected based on patient's condition. In the CALYPSO trial, the median PFS with PLD-C treatment in the platinum-free interval of 6-12 months subgroup was 9.4 months, and the ORR was 39%.…”

Section: Discussionmentioning

confidence: 99%

“…It was shown that the response to PBC was poor at the time of recurrence after olaparib maintenance therapy. The first choice of PBC in our institution is PLD‐C, owing to the high efficacy and low incidence of carboplatin hypersensitivity reactions in the CALYPSO trial and our study 6,7 . Other platinum‐based combinations or carboplatin monotherapy were selected based on patient's condition.…”

Section: Discussionmentioning

confidence: 99%

Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum‐based chemotherapy

Nakazawa

Nagao

Narita

et al. 2022

J of Obstet and Gynaecol

Self Cite

View full text Add to dashboard Cite

Aim: Several years have passed since olaparib maintenance therapy was approved in patients with platinum sensitive recurrent ovarian cancer (PSROC). We speculated that the response to platinum-based chemotherapy (PBC) would be impaired at the time of recurrence after olaparib maintenance therapy. We conducted a noninterventional retrospective study to clarify this clinical question in a single institution. Methods: We included all patients with PSROC who received olaparib after second or later line of PBC between April 18, 2018, and August 31, 2021. We evaluated the effect of olaparib maintenance therapy on PBC after progression. Results: We identified 42 patients who received olaparib maintenance therapy after second or later line of PBC. Twenty-four patients relapsed after olaparib maintenance therapy, and 17 patients received PBC again. Four of 17 patients (complete response 2, partial response 2) responded to the PBC. The median progressionfree survival was longer in patients with platinum-free interval ≥12 months than platinum-free interval of 6-12 months (9.7 vs 2.6 months, hazard ratio, 0.20: 95% confidence interval, 0.04-0.90; p = 0.04). Conclusions: In the patients with PSROC who experienced disease progression after olaparib maintenance therapy, especially in those with platinum-free interval of 6-12 months, the response to subsequent PBC was extremely poor. The efficiency of re-administration of PBC for PSROC patients with a short-term recurrence after olaparib treatment may need to be reconsidered.

show abstract

Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature

Giannone

Scotto

Katsaros

et al. 2021

Gynecologic Oncology

View full text Add to dashboard Cite

Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy

Cited by 3 publications

References 18 publications

Hypersensitivity Reaction to Carboplatin in Gynecologic Cancer: A Case Report and a Review of the Literature

Hypersensitivity Reaction to Carboplatin in Gynecologic Cancer: A Case Report and a Review of the Literature

Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum‐based chemotherapy

Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature

Contact Info

Product

Resources

About